Morgan Stanley retain $149 price target, page-25

First 25 Last

Share
Profile

Follow
Nava87

198 Posts.

23

07/05/21

23:43

Post #: 53031552
Share

Originally posted by dns123: ↑

Afterpay Ltd (ASX: APT)Another note out of Morgan Stanley reveals that its analysts have retained their overweight rating and $149.00 price target on this payments company’s shares. According to the note, the broker’s research indicates that app downloads in the United States remain strong. And while they were lower than in March, it believes this was due to the Afterpay Day sales event during that month. In addition to this, the broker is positive on the company’s European expansion, which it sees as a step towards building a global platform. The Afterpay share price is fetching $96.97 today.

Expand

Please don’t dream. It will take another 2years or May be longer to reach apt $149/share. My apologies if hurts you

Originally posted by dns123: ↑

Afterpay Ltd (ASX: APT)Another note out of Morgan Stanley reveals that its analysts have retained their overweight rating and $149.00 price target on this payments company’s shares. According to the note, the broker’s research indicates that app downloads in the United States remain strong. And while they were lower than in March, it believes this was due to the Afterpay Day sales event during that month. In addition to this, the broker is positive on the company’s European expansion, which it sees as a step towards building a global platform. The Afterpay share price is fetching $96.97 today.

Expand

APT Price at posting: $95.38 Sentiment: Sell Disclosure: Not Held
1 Upvote

0 Great analysis

Reply

Top Stories

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

PL3

Patagonia looks to raise $2.15M for South American exploration and development

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally